We originally posted the results from the ICT-107 Glioblastoma (GBM) Clinical Trial back in September 29, 2011 and marked it as a potential game changer in treatment of brain tumors. In short, ICT-107 is a vaccine based on dendritic cells, which... [Learn More...]
The post Update of ICT-107 Glioblastoma Clinical Trial: I C Great Potential In Dendritic Cell Therapies. appeared first on CTOAM.